Tradewinds LLC. Sells 490 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Tradewinds LLC. lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,696 shares of the biopharmaceutical company’s stock after selling 490 shares during the quarter. Tradewinds LLC.’s holdings in Gilead Sciences were worth $450,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in GILD. Southland Equity Partners LLC grew its position in shares of Gilead Sciences by 3.6% in the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 110 shares during the period. Berkshire Bank lifted its stake in Gilead Sciences by 3.4% in the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 111 shares during the last quarter. CFO4Life Group LLC grew its holdings in Gilead Sciences by 2.7% during the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock worth $394,000 after purchasing an additional 112 shares during the period. Howe & Rusling Inc. increased its position in Gilead Sciences by 2.5% during the fourth quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company’s stock worth $435,000 after buying an additional 115 shares during the last quarter. Finally, GHP Investment Advisors Inc. raised its stake in Gilead Sciences by 1.1% in the fourth quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock valued at $1,049,000 after buying an additional 122 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Trading Up 0.2 %

Shares of GILD stock opened at $112.05 on Tuesday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock has a market cap of $139.54 billion, a price-to-earnings ratio of 302.84, a PEG ratio of 0.71 and a beta of 0.21. The stock has a 50-day moving average of $105.88 and a 200-day moving average of $95.20.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.82%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. Gilead Sciences’s payout ratio is currently 854.05%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 302,785 shares of company stock worth $30,503,250 in the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of several research reports. Oppenheimer raised their price target on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a report on Tuesday, March 4th. Piper Sandler lifted their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Wells Fargo & Company increased their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Finally, Royal Bank of Canada increased their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $105.12.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.